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Background: There is growing interest in the anesthetic approach using total intravenous anesthesia (TIVA) with 
propofol and remifentanil for the prevention of postoperative nausea and vomiting (PONV). The aim of this study was 
to compare between the two anesthetic techniques for preventing PONV in the patients undergoing mastoidectomy 
with tympanoplasty. 
Methods: After obtaining informed consent, 62 patients aged between 20 to 60 years undergoing elective 
mastoidectomy and tympanoplasty were randomized into two equal study groups: group P/R (n = 31) included 
patients undergoing TIVA with propofol and remifentanil, and group S/R (n = 31) included patients undergoing 
balanced anesthesia with sevoflurane and remifentanil. The incidences of PONV and complete response (no PONV, 
no rescue) were assessed at 1 and 24 h after surgery, using the Rhodes Index. Also, the usage of rescue antiemetics 
and pain intensity were recorded. 
Results: The Rhodes Index including the occurrence score, distress score and experience score was significantly 
lower in the P/R group compared to that in the S/R group during the study period (P < 0.05), and the incidence of 
complete response was significantly higher in the P/R group compared to that in the S/R group, during the first 24 h 
after surgery. 4 patients in the S/R group requested antiemetics during the first 1 h after surgery. There were no 
significant differences in pain intensity among groups. 
Conclusions: Compared to balanced anesthesia with sevoflurane and remifentanil, TIVA with propofol and 
remifentanil was followed by significantly lower incidence and severity of PONV.  (Korean J Anesthesiol 2011; 61: 399-404)
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Introduction
Postoperative nausea and vomiting (PONV) is a common, 
unpleasant, and exhausting complication that may occur after 
surgery and can lead to increased recovery room time, potential 
hospital admission, and increased total health care costs [1]. 
Expert anesthesiologists have ranked PONV during induction 
as second among 33 clinical anesthesia outcomes in frequency 
and importance [2]. PONV is one of the most frequently 
encountered complaints after middle ear surgery. It has been 
reported that 50-80% of the patients who undergo middle ear 
surgery experience PONV [3-5]. This incidence may justify the 
use of prophylactic antiemetics for the prevention of PONV 
after middle ear surgery. Numerous antiemetics, such as 5-HT3 
antagonists, dopamine receptor antagonists, and antihistamine 
drugs have been studied for the prevention of PONV after 
middle ear surgery. However, each of these treatments is 
associated with critical limiting factors and none of the available 
antiemetics is entirely effective after middle ear surgery in adult 
patients [6]. 
Anesthesia-related factors that affect the incidence of PONV 
include intraoperative anesthetic drugs and techniques [7]. 
Previous study has shown that volatile anesthetics were the 
leading cause of early postoperative vomiting and the pro-
emetic effect was larger than other risk factors [8,9]. Therefore, 
the most logical approach for prevention of PONV would be the 
omission of volatile anesthetics and nitrous oxide using a total 
intravenous anesthesia with propofol [9]. 
Propofol (2,6-diisopropylphenol), an intravenous hypnotic, 
has been a popular choice for both induction and maintenance 
of general anesthesia owing to its rapid onset, short duration 
of action and low incidence of PONV. A total intravenous 
anesthesia (TIVA) regimen with remifentanil and propofol is a 
useful anesthetic technique, effectively controlling responses 
to tracheal intubation and intense surgical stimulation, 
while allowing for rapid emergence from anesthesia without 
prolonged respiratory depression [10,11]. 
There is growing interest in the anesthetic approach using 
TIVA with propofol and remifentanil for the prevention of post-
operative nausea and vomiting. A recent study demonstrated 
that compared to volatile anesthetics, TIVA resulted in a 
significantly lower incidence of PONV in day-case surgery [12-
14]. However, there are no previous reports on the anesthetic 
approach using TIVA with propofol and remifentanil for the 
prevention of postoperative nausea and vomiting after middle 
ear surgery. 
The aim of this study was to compare between the two 
anesthetic techniques of TIVA with propofol-remifentanil and 
balanced anesthesia with sevoflurane-remifentanil for pre-
venting PONV in the adult patients undergoing mastoidectomy 
with tympanoplasty.
Materials and Methods
After obtaining approval from the institutional review board 
and informed consent of subjects, the study was prospectively 
carried out in 62 patients, ASA (American Society of Anesthesio-
logists) physical status I or II aged between 20 to 60 years, 
who underwent general anesthesia for tympanoplasty and 
mastoidectomy. Patients with gastrointestinal disease, a history 
of motion sickness, or a previous episode of PONV, and those 
who had received any opioid, steroid, or antiemetic medication 
within 24 h before surgery, and those who were pregnant or 
menstruating were excluded. 
No premedication was administered before the induction. 
Patients were transferred to the operating room where they 
were monitored continuously with electrocardiogram, pulse 
oximetry, non-invasive arterial pressure and Bispectral Index 
score (BIS) monitoring, inspiratory oxygen concentration (FIO2) 
and end-tidal CO2 (EtCO2). Also, nasopharyngeal temperature 
was monitored and maintained with 36.5 ± 1
oC throughout 
surgery. Patients were randomly assigned, according to a 
computer-generated random number table, to receive one of 
the following two anesthetic techniques: general anesthesia 
using sevoflurane and remifentanil (S/R group) or total 
intravenous anesthesia with propofol-remifentanil (P/R group). 
Age, weight, height, volume of fluids during anesthesia and 
duration of surgery and anesthesia were recorded. 
Before anesthesia induction, all patients breathed 100% 
oxygen for 5 min and received an intravenous (IV) fluid load 
of lactated Ringer’s solution 5 ml/kg. The infusions of propofol 
and remifentanil were prepared using Fresofol 2% inj., 50 
ml vial (Fresenius Kabi, Austria) and Ultiva
TM inj., 1 mg vial 
(GlaxoSmithKline, Belgium), respectively. Remifentanil 1 mg 
was diluted into 50 ml of normal saline (20 mg/ml solution). A 
commercial target controlled infusion (TCI) pump (Orchestra
Ⓡ
Base Primea, Fresenius Vial, France) was used for the effect-
site TCI of propofol and remifentanil. The pump used was 
the Marsh and colleagues [15] and Minto and colleagues [16] 
models for propofol and remifentanil, respectively.
The P/R group received remifentanil to a target effect-site 
concentration (Ce) of 3 ng/ml. When the intended target Ce of 
remifentanil was reached, TCI of propofol was then started at a 
target Ce of 3.5 mg/ml. The drug infusions were continued until 
the patient fell asleep and tracheal intubation was facilitated 
by rocuronium 0.6 mg/kg. The patients were mechanically 
ventilated with 50% oxygen and air to maintain EtCO2 between 
30 and 35 mmHg, and anesthesia was maintained with 
continuous infusion of remifentanil and propofol infusion using 
TCI device according hemodynamic response and Bispectral 401 www.ekja.org
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Index (BIS) score. The target concentrations of propofol and 
remifentanil were adjusted in increments or decrements of 0.2 
ng/ml and 0.2 μg/ml, respectively, every minute to maintain the 
BIS between 40 and 60. 
Patients assigned to the S/R group received remifentanil to 
a target Ce of 3 ng/ml followed by propofol 2 mg/kg IV. After 
the loss of the eyelash reflex, the patients were intubated with 
endotracheal tube after administration of rocuronium 0.6 mg/
kg. The patients were mechanically ventilated with 50% oxygen 
and air, and anesthesia was maintained with sevoflurane 
1.0 to 3.0 vol% and continuous remifentanil infusion using 
TCI device. At the end of surgery, glycopyrrolate 7 μg/kg and 
pyridostigmine 30 μg/kg were administered intravenously 
for the antagonism of residual neuromuscular blockade. A 
nasogastric tube was inserted to empty the stomach and it was 
removed before extubation of the tracheal tube. Pain intensity 
scores were measured with a visual analog scale (VAS) ranging 
from 0 (no pain) to 10 (the worst possible pain). First-line 
analgesic treatment was with ketorolac 30 mg IV when the 
patient asked for an analgesic. If the patient did not respond to 
the initial treatment, pethidine 25 mg IV followed as second-
line treatment. 
All episodes of PONV (nausea, retching, and vomiting) during 
the periods 0 to 1 h and 1 to 24 h after anesthesia were recorded 
by investigators who were unaware of the anesthetic technique 
used in each patient. Nausea was defined as the subjectively 
unpleasant sensation associated with awareness of the urge to 
vomit; retching was defined as the labored, spastic, rhythmic 
contraction of the respiratory muscles without expulsion of 
the gastric contents; and vomiting was defined as the forceful 
expulsion of gastric contents from the mouth [7]. At the end 
of each observation period, patients evaluated the severity of 
PONV using the Rhodes Index [17] (Table 1). Complete response 
(i.e., emesis-free) was defined as no PONV and no need for 
another rescue antiemetic medication. Rescue antiemetics 
were administered for active nausea and vomiting defined 
above. First-line rescue treatment was with metoclopramide 
10 mg IV. If the patient did not respond to the initial treatment, 
ondansetron 4 mg IV followed as second-line treatment. 
Based on previous studies [3-5], the predicted incidence 
of PONV in this study was in the region of 70 percent. It was 
decided that a 30% reduction in the incidence of PONV in the 
P/R group would be clinically relevant. The α error was set at 0.05 
(two-sided) and the β error at 0.02 (power = 0.8). This analysis 
showed that 28 patients were necessary in each group. We 
assumed a dropout rate of 10%, and so we increased the sample 
size to 31 patients per group. Statistical analyses were performed 
using SPSS software (version 15.0, SPSS Inc., IL, USA). Analysis 
of variance with Bonferroni’s correction, the χ
2 test, Fisher’s 
exact test, or the Mann-Whitney U-test was performed where 
appropriate. A P value of < 0.05 was considered significant. 
Values were expressed as means (SD), or number of patients (%). 
Results
No statistically significant differences were observed with 
respect to age, body weight, height, sex ratio, fluid volume 
during anesthesia, duration of anesthesia and surgery between 
the two groups (Table 2).
The Rhodes Index was significantly lower in the P/R group 
Table 1.  Rhodes Index of Nausea, Vomiting, and Retching (RINVR)
1. In the last ( ) hours, I threw up ○○ times.
2. In the last ( ) hours, from retching and 
dry heaves, I have felt ○○ distress.
3. In the last ( ) hours, from vomiting or 
throwing up, I have felt ○○ distress.
4. In the last ( ) hours, I have felt nauseated 
or sick to my stomach.
5. In the last ( ) hours, from nausea/
sickness to my stomach, I have felt  
○○ distress.
6. In the last ( ) hours, each time I threw up, 
I produced a ○○ amount.
7. In the last ( ) hours, I have felt nauseated 
or sick to my stomach ○○ times.
8. In the last ( ) hours, I have had periods of 
retching or dry heaves without bringing 
anything up ○○ times.
7 or more
(4)
No
(0)
Severe
(4)
Not at all
(0)
No
(0)
Very large
(3 cups or more)
(4)
7 or more
(4)
No
(0)
5-6
(3)
Mild
(1)
Great
(3)
1 hour or less
(1)
Mild
(1)
Large
(2-3 cups)
(3)
5-6
(3)
1-2
(1)
3-4
(2)
Moderate
(2)
Moderate
(2)
2-3 hours
(2)
Moderate
(2)
Moderate
(1/2-2 cups)
(2)
3-4
(2)
3-4
(2)
1-2
(1)
Great
(3)
Mild
(1)
4-6 hours
(3)
Great
(3)
Small
(up to 1/2 cups)
(1)
1-2
(1)
5-6
(3)
I did not throw up
(0)
Severe
(4)
No
(0)
More than 6 hours
(4)
Severe
(4)
I did not
throw up
(0)
No
(0)
7 or more
(4)
Total experience score: sum of all scores, total occurrence score: 1 + 4 + 6 + 7 + 8, total distress score: 2 + 3 + 5.402 www.ekja.org
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compared to that in the S/R group during the first 24 hrs after 
surgery (Table 3). The Rhodes Index including the occurrence 
score and distress score and experience score was significantly 
lower in the P/R group (0.06, 0.06 and 0.13, respectively) 
compared to that in the S/R group (1.00, 0.87 and 1.87, respec-
tively), during the first 1 h after surgery. Also, during 1-24 h 
after surgery, the Rhodes Index was significantly lower in the P/
R group (0.13, 0.06 and 0.19, respectively) compared to that in 
the S/R group (0.81, 0.45 and 1.26, respectively). The incidence 
of complete response was significantly higher in the P/R group 
compared to that in the S/R group, during the first 24 h after 
surgery (Table 3). The incidence of complete response in the P/
R and S/R groups was: 97 97.5% and 61%, respectively, during 
the first 1 h; and 97% and 81%, respectively, during 1 to 24 h 
after surgery. 4 patients in the S/R group requested antiemetics 
during the first 1 h after surgery (Table 3). There were no 
statistically significant differences in the VAS scores and in the 
proportion of patients who required rescue analgesics during 
the study period between the P/R and S/R groups (Table 4). 
Discussion
In this study, the Rhodes Index including the occurrence 
score, distress score and experience score was significantly 
lower in the P/R group compared to that in the S/R group during 
the study period, and the incidence of complete response was 
significantly higher in the P/R group compared to that in the S/
R group. Also, the proportion of patients who required rescue 
antiemetics was significantly lower in the P/R group compared 
to that in the S/R group, during the first 1 hour after surgery. 
The cause of PONV is probably a multifactorial origin. The 
risk factors include patient-related factors such as gender, 
nonsmoking status, past history of motion sickness and/
or previous PONV, surgical anesthesia technique, and post-
operative pain [7]. Since vomiting after middle ear surgery may 
be due to increased pressure in the middle ear [18], we did not 
use nitrous oxide, which would increase the pressure in the 
middle ear. Rhodes and McDaniel [17] developed the Index of 
Nausea and Vomiting (INV) to capture the multidimensional 
features of upper gastrointestinal distress. The Rhodes Index 
was tested and found to be a valid and reliable instrument 
for measuring upper gastrointestinal distress. In the present 
study, the Rhodes Index was used instead of a simple numeric 
rating scale to measure the efficacy of TIVA with propofol and 
remifentanil. 
There is now strong evidence that volatile anesthetics are 
emetogenic and that there are no meaningful differences 
between halothane, enflurane, isoflurane, sevoflurane, and 
desflurane in this respect [9]. A number of treatments have been 
introduced in order to reduce PONV after middle ear surgery, 
such as 5-HT3 antagonists, dopamine receptor antagonists, 
and antihistamine drugs. However, each of these treatments is 
associated with critical limiting factors, namely cost with 5-HT3 
antagonists, extrapyramidal symptoms with dopamine receptor 
antagonists and excessive sedation, and tachycardia with 
Table 2.  Patient Characteristics 
S/R group
(n = 31)
P/R group
(n = 31)
P value
Sex (M/F)
Age (yrs)
Weight (kg)
Height (cm)
Volume of fluids during 
  anesthesia (ml/kg)
Duration of operation (min)
Duration of anesthesia (min)
13/18
49.1 ± 11.1
60.3 ± 12.8
162.5 ± 15.4
21.2 ± 7.3
133.4 ± 26.2
169.2 ± 25.0
14/17
47.3 ± 13.0
61.3 ± 8.5
161.5 ± 13.8
19.2 ± 5.0
130.0 ± 28.6
166.8 ± 28.4
0.802
0.773
0.438
0.441
0.153
0.224
0.493
The values are shown as means ± SD or number of patients.  There 
were no significant differences between groups. 
Table 3.  Rhodes Index of Nausea, Vomiting and Retching (RINVR) 
and Incidence of Complete Response
S/R group
(n = 31)
P/R group
(n = 31)
P value
During 0-1 hr
    Complete response
    Occurrence score
    Distress score
    Experience score
    Rescue antiemetics
During 1-24 hr 
    Complete response
    Occurrence score
    Distress score
    Experience score
    Rescue antiemetics
19 (61.3%)
1.00 ± 1.57
0.87 ± 1.41
1.87 ± 2.94
4 (12.9%)
25 (80.6%)
0.81 ± 2.01
0.45 ± 1.09
1.26 ± 3.09
0 (0%)
30 (96.8%)*
0.06 ± 0.36*
0.06 ± 0.36*
0.13 ± 0.72*
0 (0%)
30 (96.8%)*
0.13 ± 0.72*
0.06 ± 0.36*
0.19 ± 1.08*
0 (0%)
0.001
0.001
0.001
0.001
0.078
0.047
0.048
0.047
0.049
0.317
The values are shown as means ± SD or number of patients.  *P < 0.05 
between two groups. 
Table 4.  Pain Intensity and Analgesics Used Postoperatively 
S/R group
(n = 31)
P/R group
(n = 31)
P value
During 0-1 h
    Pain intensity
    Analgesics used postoperatively
        Tarasyn
        Pethidine
During 1-24 h
    Pain intensity
    Analgesics used postoperatively 
        Tarasyn
        Pethidine
3.27 ± 0.96
11 (35.5%)
2 (6.5%)
1.90 ± 0.79
12 (38.7%)
1 (3.2%)
3.07 ± 1.20
8 (25.8)
1 (3.2%)
2.11 ± 0.76
15 (45.2%)
1 (3.2%)
0.417
0.412
0.557
0.399
0.446
1.000
The values are shown as means ± SD or number of patients.  There 
were no significant differences between groups. 403 www.ekja.org
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antihistamine drugs [19-21]. In patients at high risk for PONV, 
it would therefore make better sense to avoid inhalational 
anesthesia rather than simply to add an antiemetic [8,9]. 
In this study, the incidence and severity of PONV was signifi-
cantly lower in the group that received TIVA with propofol and 
remifentanil compared to the group that received sevoflurane 
and remifentanil, during the first 24 hours after surgery. Also, 
the proportion of patients that required rescue antiemetics 
was significantly lower in the group that received TIVA with 
propofol and remifentanil compared with the group that 
received sevoflurane and remifentanil, during the first 1 hour 
after surgery. These results were in agreement with previous 
studies [12,22]. It has been reported that maintenance of 
anesthesia with sevoflurane results in a higher incidence of 
nausea and vomiting compared with propofol in a standardized 
outpatient population [22]. Also, Ionescu et al. [12] has reported 
that compared with isoflurane, total intravenous anesthesia 
(TIVA) with propofol and remifentanil resulted in a significantly 
lower incidence of PONV during the first 24 hours after surgery. 
However, Tramer et al. [13] following a meta-analysis of the 
literature, found that TIVA with propofol, rather than inhalation 
anesthesia, may have a clinically relevant effect on PONV but 
only in the short term. In addition, White et al. [14] reported that 
because TIVA reduced the predicted rate of PONV in the early 
postoperative period only, a long-acting antiemetic drug might 
be necessary to prevent postdischarge nausea and vomiting in 
day-case surgery. It has been shown that a minimum plasma 
concentration of propofol is necessary to produce an anti-
emetic effect [23]. Since propofol has a short, context-sensitive 
half-time (less than 40 min for infusions up to 8 h), significant 
plasma-levels would be unlikely after several hours. As a 
result, propofol may need to be considered a prophylactic 
option for early PONV only. However, other factors that have 
been associated with PONV include type of surgery, choice of 
opioid, patient-age, and length of surgery [24,25]. Therefore, 
this discrepancy could be due to the differences in the protocol, 
patient characteristics and surgery. 
Also, postoperative pain affects the incidence of PONV after 
surgery [7]. The total dose of remifentanil during anesthesia was 
significantly higher in the P/R group compared to that in the S/
R group (1,210.94 ± 439 μg and 882.74 ± 437 μg, respectively) 
but there were no statistically significant differences in the VAS 
scores and in the proportion of patients who required rescue 
analgesics during the study period between the two groups. 
In this study, the Rhodes Index was significantly lower in 
the P/R group compared to that in the S/R group, during the 
first 24 hours after surgery. Also, the proportion of patients who 
required rescue antiemetics was significantly lower in the P/R 
group compared to that in the S/R group, during the first 1 hour 
after surgery. 
Interpretation of our findings should be considered within 
the context of the limitation of the study. Firstly, the sample size 
of the study was relatively small despite a sufficient number of 
patients per the results of the power analysis. Secondly, we did 
not include high-risk patients with a history of motion sickness, 
or a previous episode of PONV in our study. Future researchers 
should take these limitations into consideration. 
In conclusion, compared to balanced anesthesia with 
sevoflurane and remifentanil, TIVA was followed by significantly 
lower incidence and severity of PONV. This result suggests that 
TIVA with propofol and remifentanil may be a useful anesthetic 
approach for the reduction or prevention of postoperative 
nausea and vomiting after mastoidectomy with tympanoplasty. 
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